Daiichi Sankyo's Once-Daily Lixiana® (edoxaban) Receives Positive CHMP Opinion for the Prevention of Stroke and Systemic

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, dyslipidemia and bacterial infections used by patients around the world, the Group has also launched treatments for thrombotic disorders and is building new product franchises. Furthermore, Daiichi Sankyo research and development is focused on bringing forth novel therapies in oncology and cardiovascular-metabolic diseases, including biologics. The Daiichi Sankyo Group has created a "Hybrid Business Model," to respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit: http://www.daiichisankyo.com.

Forward-looking statements

This press release contains forward-looking statements and information about future developments in the sector, and the legal and business conditions of DAIICHI SANKYO Co., Ltd. Such forward-looking statements are uncertain and are subject at all times to the risks of change, particularly to the usual risks faced by a global pharmaceutical company, including the impact of the prices for products and raw materials, medication safety, changes in exchange rates, government regulations, employee relations, taxes, political instability and terrorism as well as the results of independent demands and governmental inquiries that affect the affairs of the company. All forward-looking statements contained in this release hold true as of the date of publication. They do not represent any guarantee of future performance. Actual events and developments could differ materially from the forward-looking statements that are explicitly expressed or implied in these statements. DAIICHI SANKYO Co., Ltd. assume no responsibility for the updating of such forward-looking statements about future developments of the sector, legal and business conditions and the company.

References

1) Centers for Disease Control and Prevention. Deep Vein Thrombosis &
Pulmonary Embolism. Available at:
http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-2-the-pr...
. [Last accessed: April 2015].
2) Giugliano R, et al. Edoxaban versus warfarin in patients with atrial
fibrillation. N Engl J Med. 2013;369(22):2093-2104.
3) Bueller H, et al. Edoxaban versus warfarin for the treatment of symptomatic
venous thromboembolism. N Engl J Med. 2013;369(15):1406-1415.
4) Iqbal MB, et al. Recent developments in atrial fibrillation. BMJ.
2005;330(7485):238-43.
5) Camm A, et al. Guidelines for the management of atrial fibrillation: the Task
Force for the Management of Atrial Fibrillation of the European Society of Cardiology
(ESC). Eur Heart J. 2010;31(19):2369-429
6) Krijthe BP, et al. Projections on the number of individuals with atrial
fibrillation in the European Union, from 2000 to 2060. Eur Heart J.2013;34(35
):2746-2751.
7) Cohen A, et al. Venous thromboembolism (VTE) in Europe. Thromb Haemost.
2007;98(4):756-764.
8) Ogata K, et al. Clinical safety, tolerability, pharmacokinetics, and
pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J
Clin Pharmacol. 2010;50(7):743-753.
9) Daiichi Sankyo press release - Daiichi Sankyo Launches New Formulation of
LIXIANA(R) 60 mg Tablets (edoxaban) in Japan. 8 Dec 2014. Available at:
http://www.daiichisankyo.com/media_inves...
. [Last accessed: April 2015].
10) Daiichi Sankyo press release - SAVAYSA(TM) (edoxaban) Now Available in U.S.
Pharmacies. 9 February 2015. Available at:
http://www.daiichisankyo.com/media_inves...
. [Last accessed: April 2015].
11) Daiichi Sankyo press release - Daiichi Sankyo's Once-Daily LIXIANA(R)
(edoxaban) Approved for the Prevention of Stroke and Systemic Embolism in Non-Valvular
Atrial Fibrillation and for the Treatment and Prevention of Recurrent Venous
Thromboembolism in Switzerland. 15 April 2015. Available at:
http://www.daiichisankyo.com/media_inves...
. [Last accessed: April 2015].

Contact

Daria Munsel (Europe)
Daiichi Sankyo Europe GmbH
Edoxaban Comm. & Product PR Europe
+49(89)7808728

Yasuki Minobe (Global)
Daiichi Sankyo Group
Corporate Communication Department
+81(3)62251126